drugset / Trial / NCT04980885
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a open label, phase Ib/II study. All patients are diagnosed with AML, Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine in subjects with AML.
Timeline
- Start
- 2021-08-13
- Primary completion
- 2025-09
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK117 | Monoclonal antibody | — | Intravenous |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |